 LONDON, March 30, 2021 GLOBE NEWSWIRE -- Achilles Therapeutics plc NASDAQ: ACHL, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares ADSs representing 9,750,000 ordinary shares at an initial public offering price of 18.00 per ADS for total gross proceeds of 175.5 million. All ADSs sold in the offering are being offered by Achilles. The ADSs are expected to begin trading on The Nasdaq Global Select Market on March 31, 2021 under the ticker symbol ACHL. In addition, Achilles has granted the underwriters a 30-day option to purchase up to an additional 1,462,500 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 6, 2021, subject to customary closing conditions. 